Your browser doesn't support javascript.
loading
Machine Learning-Based Risk Stratification for Gestational Diabetes Management.
Yang, Jenny; Clifton, David; Hirst, Jane E; Kavvoura, Foteini K; Farah, George; Mackillop, Lucy; Lu, Huiqi.
Afiliação
  • Yang J; Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7SQ, UK.
  • Clifton D; Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7SQ, UK.
  • Hirst JE; Oxford-Suzhou Centre for Advanced Research, Suzhou 215000, China.
  • Kavvoura FK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
  • Farah G; The George Institute for Global Health, Imperial College London, London WB12 0BZ, UK.
  • Mackillop L; John Radcliffe Hosptial Women's Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
  • Lu H; Centre for Diabetes & Endocrinology, Royal Berkshire Hospitals NHS Foundation Trust, Reading RG1 5BS, UK.
Sensors (Basel) ; 22(13)2022 Jun 25.
Article em En | MEDLINE | ID: mdl-35808300
Gestational diabetes mellitus (GDM) is often diagnosed during the last trimester of pregnancy, leaving only a short timeframe for intervention. However, appropriate assessment, management, and treatment have been shown to reduce the complications of GDM. This study introduces a machine learning-based stratification system for identifying patients at risk of exhibiting high blood glucose levels, based on daily blood glucose measurements and electronic health record (EHR) data from GDM patients. We internally trained and validated our model on a cohort of 1148 pregnancies at Oxford University Hospitals NHS Foundation Trust (OUH), and performed external validation on 709 patients from Royal Berkshire Hospital NHS Foundation Trust (RBH). We trained linear and non-linear tree-based regression models to predict the proportion of high-readings (readings above the UK's National Institute for Health and Care Excellence [NICE] guideline) a patient may exhibit in upcoming days, and found that XGBoost achieved the highest performance during internal validation (0.021 [CI 0.019-0.023], 0.482 [0.442-0.516], and 0.112 [0.109-0.116], for MSE, R2, MAE, respectively). The model also performed similarly during external validation, suggesting that our method is generalizable across different cohorts of GDM patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Gestacional Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Gestacional Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2022 Tipo de documento: Article